Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

 
Therapeutical Areas
Advanced Wound Care

Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

Advanced Wound Care
with Nexodyn® AOS

Wound Cleansers:
a Growing Category in a Growing Market

Advanced wound care is a fast growing market mainly composed of 4 main categories: dressings, wound cleansers, negative pressure wound therapy devices and biologics.

The global market value was $9,4 bn in 2015 and it is expected to reach $13,1 bn in 2022, with a compound annual growth rate (CAGR) of 4,7 %1.

Among the leading categories of advanced wound care, wound cleansers are expected to attain $2,1bn in 2023, growing at a CAGR of 5,4%1 from 2016 to 2023. The main drivers of this growth are the aging population and the increased prevalence of chronic diseases, such as diabetes.


Non-Healing Wounds: a Challenge for Patients and Society


It is estimated that 1 % to 2 % of the population will experience a chronic wound during their lifetime in developed countries2 and this rate is increasing year after year. Stalled wounds may persist for months, even years3,4 before healing.

Due to this situation, non-healing wounds represent an economic burden for health services and patients. In 2015 only, chronic wounds represented a global expenditure of $143 bn.

Stalled wounds also have a psychological and social impact on patients: infection, delays in wound healing and wound associated pain strongly affect patients' life.

For these reasons, reducing healing time and pain for patients has become a priority.

Our Solution to an Unmet Medical Need

Historically, wound cleansers were used solely to remove contaminants, foreign debris and exudate or for irrigation. In recent years, Wound Bed Preparation (WBP) is the emerging evidence-based approach that has been developed to promote healing of non-healing wounds.

The WBP approach is internationally recognized by the major wound care associations.

According to this, wound cleansers may actually play a crucial role to support healing by removing local barriers to healing while minimizing harm to wound tissue.

The principal local barriers to healing are bioburden & biofilm5,6 and high levels of proinflammatory mediators7-8.

Presenting Nexodyn AOS - the Wound Care Solution


Until today, no available wound cleanser matched the ideal profile in terms of safety and efficacy: an evolution is needed.

Thanks to its optimal efficacy and safety, Nexodyn AOS, the Tehclo based solution, is the first wound cleanser proven to restart healing.

Find out more about Nexodyn AOS and the evolution of wound cleansing

References

  1. Bis Research Analysis 2016. Global Advanced Wound Care Market- Analysis and forecast (2016-2022).
  2. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg. 2004;187(5):S38-S43. doi: 10.1016/S0002-9610(03)00303-9. [PubMed] [CrossRef]
  3. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Advances in wound care. 2015;4(9):560-82.
  4. Kirker KR, James GA. In vitro studies evaluating the effects of biofilms on wound-healing cells: a review. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2017;125(4):344-52.
  5. Kruse CR, The external microenvironment of healing skin wounds. Wound Repair Regen. 23(4):456-64, 2015
  6. Leaper D, Approach to chronic wound infections. Br J Dermatol. 173 (2): 351-358, 2015
  7. Nunan R, Cellular and molecular mechanisms of repair in acute and chronic wound healing, British Journal of Dermatology, 2014
  8. Diegelmann RF, Excessive neutrophils characterize chronic pressure ulcers. Wound Repair Regen.11(6):490-5,2003.
Inherited Metabolic Disorders Cancer Supportive Care
APR 2015 all rights reserved | About us | APR Products | Our services | News & Events | Contact | Privacy policy | Cookie policy | Sitemap